Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Although pharmacist intervention for patients with chronic diseases has been shown to improve medication adherence, few studies have evaluated its effects on the objective clinical outcomes. We investigated the impact of pharmacist intervention on medication adherence and clinical outcomes in patients with ulcerative colitis (UC). Methods: Patients with UC and low medication adherence were divided into two groups, based on pharmacist intervention. Their medication possession ratio and nonadherence rate for 6 months before and after the baseline were investigated. The partial Mayo score, flare-up incidence, and factors influencing flare-up events for 1 year after the baseline were analyzed. Results: Of 99 patients, 33 and 66 were included in the intervention and control groups, respectively. The nonadherence rate significantly declined in the intervention group 6 months after the baseline (60.6% before vs 30.3% after; p=0.013). The groups showed a significant difference regarding time-related partial Mayo scores (p=0.002). Intervention was significantly negatively correlated with time and the partial Mayo score (r2=0.035, p=0.013). A significant difference was observed in the flare-up incidence (33.3% in the intervention group vs 54.6% in the control group; p=0.046). Multivariate logistic regression indicated that pharmacist intervention (adjusted odds ratio, 0.370; 95% confidence interval, 0.145 to 0.945; p=0.038) independently reduced the flareup risk. Conclusions: Pharmacist intervention significantly decreased the nonadherence rate, improved the partial Mayo score, and reduced the flare-up incidence compared with the control group in a cohort of UC patients identified to have low medication adherence.
Abstract
Background/Aims: Although pharmacist intervention for patients with chronic diseases has been shown to improve medication adherence, few studies have evaluated its effects on the objective clinical outcomes. We investigated the impact of pharmacist intervention on medication adherence and clinical outcomes in patients with ulcerative colitis (UC). Methods: Patients with UC and low medication adherence were divided into two groups, based on pharmacist intervention. Their medication possession ratio and nonadherence rate for 6 months before and after the baseline were investigated. The partial Mayo score, flare-up incidence, and factors influencing flare-up events for 1 year after the baseline were analyzed. Results: Of 99 patients, 33 and 66 were included in the intervention and control groups, respectively. The nonadherence rate significantly declined in the intervention group 6 months after the baseline (60.6% before vs 30.3% after; p=0.013). The groups showed a significant difference regarding time-related partial Mayo scores (p=0.002). Intervention was significantly negatively correlated with time and the partial Mayo score (r2=0.035, p=0.013). A significant difference was observed in the flare-up incidence (33.3% in the intervention group vs 54.6% in the control group; p=0.046). Multivariate logistic regression indicated that pharmacist intervention (adjusted odds ratio, 0.370; 95% confidence interval, 0.145 to 0.945; p=0.038) independently reduced the flareup risk. Conclusions: Pharmacist intervention significantly decreased the nonadherence rate, improved the partial Mayo score, and reduced the flare-up incidence compared with the control group in a cohort of UC patients identified to have low medication adherence.
참고문헌 (34)
- Feuerstein JD, "Ulcerative colitis : epidemiology, diagnosis, and management", Mayo Clin Proc, 89, pp.1553~1563 (2014)
- Emiko Mizoguchi, "Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models", Intestinal research, 18(2), pp.151~167 (2020), 대한장연구학회[DOI]
- 박지혜, "Incidence and Prevalence of Inflammatory Bowel Disease across Asia", Yonsei Medical Journal, 62(2), pp.99~108 (2021), 연세대학교의과대학[DOI]
- Jooyoung Lee, "Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study", Gut and Liver, 14(1), pp.89~99 (2020), 거트앤리버 소화기연관학회협의회
- Sun-Ho Lee, "Changes in prevalence and perception of complementary and alternative medicine use in Korean inflammatory bowel disease patients: results of an 8-year follow-up survey", Intestinal research, 18(2), pp.192~199 (2020), 대한장연구학회[DOI]
- Gibson PR, "Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia : a cross-sectional, observational study", J Crohns Colitis, 8, pp.598~606 (2014)
- 오신주, "Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis", Intestinal research, 19(3), pp.323~331 (2021), 대한장연구학회[DOI]
- Rubin DT, "ACG clinical guideline : ulcerative colitis in adults", Am J Gastroenterol, 114, pp.384~413 (2019)
- Toshifumi Hibi, "Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis", Intestinal research, 19(1), pp.53~61 (2021), 대한장연구학회[DOI]
- Solberg IC, "Clinical course during the first 10 years of ulcerative colitis : results from a population-based inception cohort(IBSEN Study)", Scand J Gastroenterol, 44, pp.431~440 (2009)
- Webber Chan, "Medication adherence in inflammatory bowel disease", Intestinal research, 15(4), pp.434~445 (2017), 대한장연구학회
- Testa A, "Adherence in ulcerative colitis : an overview", Patient Prefer Adherence, 11, pp.297~303 (2017)
- Jackson CA, "Factors associated with non-adherence to oral medication for inflammatory bowel disease : a systematic review", Am J Gastroenterol, 105, pp.525~539 (2010)
- Burisch J, "The burden of inflammatory bowel disease in Europe", J Crohns Colitis, 7, pp.322~337 (2013)
- Herman ML, "Treatment nonadherence in inflammatory bowel disease : identification, scope, and management strategies", Inflamm Bowel Dis, 21, pp.2979~2984 (2015)
- Readdean KC, "Effect of pharmacist intervention on improving antidepressant medication adherence and depression symptomology : a systematic review and meta-analysis", Res Social Adm Pharm, 14, pp.321~331 (2018)
- Presley B, "Pharmacy-led interventions to improve medication adherence among adults with diabetes : a systematic review and meta-analysis", Res Social Adm Pharm, 15, pp.1057~1067 (2019)
- Sah SK, "Impact of pharmacist care in the management of autoimmune disorders : a systematic review of randomized control trials and non-randomized studies", Res Social Adm Pharm, 17, pp.1532~1545 (2021)
- Tiao DK, "Inflammatory bowel disease pharmacist adherence counseling improves medication adherence in Crohn’s disease and ulcerative colitis", Inflamm Bowel Dis, 23, pp.1257~1261 (2017)
- Khiani V, "The pharmacist’s role in biologic management for IBD in a health system-integrated practice model", Am J Pharm Benefits, 7, pp.215~220 (2015)
- position paper, "J Crohns Colitis", 2020, 1037~1048
- Parikh A, "Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease", Inflamm Bowel Dis, 19, pp.1691~1699 (2013)
- Lewis JD, "Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis", Inflamm Bowel Dis, 14, pp.1660~1666 (2008)
- Kuriyama M, "Prediction of flare-ups of ulcerative colitis using quantitative immunochemical fecal occult blood test", World J Gastroenterol, 16, pp.1110~1114 (2010)
- Baumgart DC, "Vedolizumab induction therapy for inflammatory bowel disease in clinical practice : a nationwide consecutive German cohort study", Aliment Pharmacol Ther, 43, pp.1090~1102 (2016)
- Kapasi R, "Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK", Frontline Gastroenterol, 11, pp.178~187 (2019)
- Conn VS, "Patient-centered outcomes of medication adherence interventions : systematic review and meta-analysis", Value Health, 19, pp.277~285 (2016)
- LaRosa JC, "Poor compliance : the hidden risk factor", Curr Atheroscler Rep, 2, pp.1~4 (2000)
- Ardizzone S, "Coated oral 5-aminosalicylic acid(Claversal)is equivalent to sulfasalazine for remission maintenance in ulcerative colitis : a double-blind study", J Clin Gastroenterol, 21, pp.287~289 (1995)
- Fukuda T, "The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy : a report from the IBD registry", PLoS One, 12, pp.e0187737~ (2017)
- Khan N, "Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis", Dig Dis Sci, 58, pp.2963~2969 (2013)
- Naegeli AN, "and modified permutations of the Mayo score : characterizing clinical and patient-reported outcomes in ulcerative colitis patients", Crohns Colitis 360, 3, pp.otab007~ (2021)
- Li J, "Systematic review with meta-analysis : fecal calprotectin as a surrogate marker for predicting relapse in adults with ulcerative colitis", Mediators Inflamm, 2019, pp.2136501~ (2019)